Biocon gets DCGI node for use of cytoserb in critical Kovid-19 cases

Biocon gets DCGI node for use of cytoserb in critical Kovid-19 cases

Let’s Start this Interesting Article Shared on

BENGALURU: Biocon said its subsidiary Biocon Biologics has been received by the Drugs Controller General of India (DCGI) for an extracorporeal blood purification (EBP) device CytoSorb, which confirmed or confirmed IC patients admitted to adjacent ICs. Has to reduce the level of pro-inflammatory cytosine. respiratory failure.
Biocon Biologics has been licensed for emergency use of CytoSorb by drug regulators on patients 18 years of age or older. Biocon said on Wednesday that the license would remain in effect until the outbreak is controlled.
This has come at a time when the US Food and Drug Administration (FDA) allowed the emergency use of cytosorb for use in Koronova-affected patients.
“CytoSorb is a licensed unique device that reduces cytokine storms in critically ill patients and was introduced in India by Biocon in 2013. DCGI Approval for Emergency Use of CytoSorb for Critical Covid-19 Patients and Industry An important example for regulators. Working together to provide immediate access to physicians and patients, “said Kiran Mazumdar-Shaw, Executive Chairman.
Studies have shown that Kovid-19 patients who develop severe complications experience a cytokine storm, also known as cytokine release syndrome (CRS), that causes excessive inflammation, organ failure, and death. is. The goal of cytosorb therapy is to reduce the lethal inflammatory response through cytokine storms and blood purification so that this injury can be reduced or prevented.


Leave a Reply

Your email address will not be published. Required fields are marked *